Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease

Murakami, Yu; Kakeda, Shingo; Watanabe, Keita; Ueda, Issei; Ogasawara, Atsushi; Moriya, Junji; Ide, Satoru; Futatsuya, Koichiro; Satô, Tôru; Okada, Kazumasa; Uozumi, Tohru; Tsuji, Sadatoshi; Liu, T.; Wang, Y.; Korogi, Yukunori

doi:10.3174/ajnr.a4260

Cited by 134 publications

(141 citation statements)

References 46 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Susceptibility weighted imaging at 3 Tesla has also been able to detect absence of nigrosomes in PD (Schwarz et al, 2014). Susceptibility mapping has shown increased magnetic susceptibility in the substantia nigra, consistent with increased iron content in PD (Loftipour et al, 2012; Murakami et al, 2015). Susceptibility mapping in PD patients has also shown improved imaging of the subthalamic nucleus and globus pallidus internus, both important regions for neurosurgical placement of electrodes for DBS (Liu, T. et al, 2013).…”

Section: Neuroimaging Of Pdmentioning

confidence: 81%

Neuroimaging of Parkinson's disease: Expanding views

Weingarten

Sundman

Hickey

et al. 2015

Neuroscience & Biobehavioral Reviews

137

View full text Add to dashboard Cite

Advances in molecular and structural and functional neuroimaging are rapidly expanding the complexity of neurobiological understanding of Parkinson’s disease (PD). This review article begins with an introduction to PD neurobiology as a foundation for interpreting neuroimaging findings that may further lead to more integrated and comprehensive understanding of PD. Diverse areas of PD neuroimaging are then reviewed and summarized, including positron emission tomography, single photon emission computed tomography, magnetic resonance spectroscopy and imaging, transcranial sonography, magnetoencephalography, and multimodal imaging, with focus on human studies published over the last five years. These included studies on differential diagnosis, co-morbidity, genetic and prodromal PD, and treatments from L-DOPA to brain stimulation approaches, transplantation and gene therapies. Overall, neuroimaging has shown that PD is a neurodegenerative disorder involving many neurotransmitters, brain regions, structural and functional connections, and neurocognitive systems. A broad neurobiological understanding of PD will be essential for translational efforts to develop better treatments and preventive strategies. Many questions remain and we conclude with some suggestions for future directions of neuroimaging of PD.

show abstract

Section: Neuroimaging Of Pdmentioning

confidence: 81%

Neuroimaging of Parkinson's disease: Expanding views

Weingarten

Sundman

Hickey

et al. 2015

Neuroscience & Biobehavioral Reviews

137

View full text Add to dashboard Cite

show abstract

“…These can be better observed in susceptibility maps than in simultaneously acquired R 2 * maps (Du et al, 2015;Murakami et al, 2015). This points towards either using multi-echo protocols covering a range of echo times up to 30ms, which will be sufficiently robust to compute R 2 * and susceptibility maps of deep gray matter regions, or single echo acquisitions with a TE~15-20ms and low BW to maximize SNR, and be able to compute susceptibility maps.…”

Section: Study Of Neurodegenerative Diseases and Agingmentioning

confidence: 94%

How to choose the right MR sequence for your research question at 7 T and above?

Marques

Norris

2018

NeuroImage

View full text Add to dashboard Cite

“…QSM has been actively applied to study the brains of PD patients (128,129), demonstrating greater sensitivity than R2* in identifying increased nigral iron in PD patients as compared to healthy controls (130-135). The voxel-based morphology analysis by Du et al (132) elegantly demonstrates selective SNc iron increase in perfect concordance with post mortem histology, underscoring the potential of QSM as a biophysical marker for therapeutic effects in clinical trials.…”

Section: Clinical Applications Enabled By Qsm Biometal Imagingmentioning

confidence: 99%

“…Devos, et al have recently reported very encouraging results showing that DFP improves PD motor performance and reduces nigral R2* values on GRE MRI, suggesting that DFP can be the first disease-modifying therapy for PD (127). Because QSM is superior to R2* for evaluating nigral iron (131,132,134,135,145), an important potential application of QSM in PD is to measure DFP's effectiveness of target-engagement in clinical trials.…”

Section: Clinical Applications Enabled By Qsm Biometal Imagingmentioning

confidence: 99%

Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care

Wang

Spincemaille

Liu

et al. 2017

Magnetic Resonance Imaging

215

199

View full text Add to dashboard Cite

Quantitative susceptibility mapping (QSM) has enabled MRI of tissue magnetic susceptibility to advance from simple qualitative detection of hypointense blooming artifacts to precise quantitative measurement of spatial biodistributions. QSM technology may be regarded to be sufficiently developed and validated to warrant wide dissemination for clinical applications of imaging isotropic susceptibility, which is dominated by metals in tissue, including iron and calcium. These biometals are highly regulated as vital participants in normal cellular biochemistry, and their dysregulations are manifested in a variety of pathologic processes. Therefore, QSM can be used to assess important tissue functions and disease. To facilitate QSM clinical translation, this review aims to organize pertinent information for implementing a robust automated QSM technique in routine MRI practice and to summarize available knowledge on diseases for which QSM can be used to improve patient care. In brief, QSM can be generated with postprocessing whenever gradient echo MRI is performed. QSM can be useful for diseases that involve neurodegeneration, inflammation, hemorrhage, abnormal oxygen consumption, substantial alterations in highly paramagnetic cellular iron, bone mineralization, or pathologic calcification; and for all disorders in which MRI diagnosis or surveillance requires contrast agent injection. Clinicians may consider integrating QSM into their routine imaging practices by including gradient echo sequences in all relevant MRI protocols.

show abstract

Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease

Cited by 134 publications

References 46 publications

Neuroimaging of Parkinson's disease: Expanding views

Neuroimaging of Parkinson's disease: Expanding views

How to choose the right MR sequence for your research question at 7 T and above?

Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care

Contact Info

Product

Resources

About